Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 57, Issue 7, Pages 3012-3020Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02252-12
Keywords
-
Categories
Funding
- American Proficiency Institute (API)
- Anacor
- Astellas
- AstraZeneca
- Bayer
- Cempra
- Cerexa
- Contrafect
- Cubist
- Daiichi
- Dipexium
- Enanta
- Furiex
- GlaxoSmithKline
- Johnson & Johnson (Ortho McNeil)
- LegoChem Biosciences Inc.
- Meiji Seika Kaisha
- Merck
- Nabriva
- Novartis
- Pfizer (Wyeth)
- Rempex
- Rib-X Pharmaceuticals
- Seachaid
- Shionogi
- The Medicines Co.
- Theravance
- ThermoFisher
Ask authors/readers for more resources
Enterobacteriaceae bacteremia isolates (n = 195; 6.4% overall) collected from 26 U.S. hospitals located in 20 states were screened for various beta-lactamase classes. A total of 175 isolates carried one to eight acquired beta-lactamase genes of 44 types that were detected in 55 combinations. Eighty-five (43.6%) strains carried bla(CTX-M), and bla(CTX-M-15) was the most prevalent (33.8%). Genes encoding OXA-1/30 (often associated with bla(CTX-M-15)), CMY-2, SHV extended-spectrum beta-lactamase (ESBLs), and TEM-1 were also prevalent. Among 33 carbapenem-resistant strains, 28 carried bla(KPC-2) or bla(KPC-3) (17 and 11 strains, respectively), and those were recovered mostly in the New York City area (16 strains) and Houston, TX (9 strains). Fourteen new SHV variants were identified among Klebsiella pneumoniae isolates carrying one or multiple SHV alleles, three carrying G238S and/or E240K amino acid alterations that confer ESBL activity. Only two of eight K. oxytoca isolates carried acquired beta-lactamases, but most had mutations on the bla(OXY) promoter region, and three new OXY-encoding genes were characterized. Concordance between a commercial nucleic acid-based microarray (Check-MDR CT101) and reference methods was noted for 105/109 (97.2%) strains. Thirty-two strains having genes that are not targeted by the commercial system were detected (OXA ESBLs, PER, PSE, or intrinsic genes). Overall, a great variety of enzymes were observed, with numerous strains carrying multiple genes. Rates of CTX-M-producing strains appear to be increasing in U.S. hospitals (26.6% in 2007 to 43.8% for 2010) participating in the SENTRY Program. Furthermore, the Check-Points system seems to be a reliable, robust, and user-friendly assay for detection of enzyme-mediated resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available